Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors.
Cancer Invest
; 29(1): 56-61, 2011 Jan.
Article
em En
| MEDLINE
| ID: mdl-21166499
ABSTRACT
INTRODUCTION:
High relapse rates and infections remain primary causes of failure in nonmyeloablative transplantation. Interleukin-2 (IL-2) may stimulate the immune system and improve outcomes. The primary objective of this pilot study was to evaluate the feasibility of administering IL-2 following a T-cell-depleted nonmyeloablative hematopoietic stem cell transplant.METHODS:
Patients received T-cell-depleted nonmyeloablative transplant from a matched or mismatched related donor. Those with allogeneic engraftment,RESULTS:
Eight patients aged 28-69 years were treated. Significant toxicities were limited to GVHD of the skin ≤grade 2 in 3 patients and severe fatigue in 4 patients, limiting the duration of therapy. Two of the 8 patients died of relapsed disease and 1 from CMV. With a median overall duration of follow-up of survivors of 48 months, 5 patients (63%) remain alive and in continuous complete remission.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Doadores de Tecidos
/
Síndromes Mielodisplásicas
/
Interleucina-2
/
Transplante de Células-Tronco Hematopoéticas
/
Histocompatibilidade
/
Antígenos HLA
/
Neoplasias
/
Antineoplásicos
Tipo de estudo:
Etiology_studies
Limite:
Adult
/
Aged
/
Humans
/
Middle aged
País como assunto:
America do norte
Idioma:
En
Ano de publicação:
2011
Tipo de documento:
Article